Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.54 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.53 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.53 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | FBP1 | P09467 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.53 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.53 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.53 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7909170 | 0.99 | MEN1 (0.57) | MEN1KMT2AADORA3EHMT1ADORA1 | |
| SCHEMBL120562 | 0.89 | ADORA3 (0.68) | MEN1KMT2AADORA3EHMT1EHMT2 | |
| SCHEMBL120551 | 0.88 | ADORA3 (0.69) | MEN1KMT2AADORA3EHMT1EHMT2 | |
| SCHEMBL7896942 | 0.86 | ADORA1 (0.55) | MEN1KMT2AADORA3ADORA1DNPH1 | |
| SCHEMBL8626012 | 0.86 | ADORA3 (0.64) | MEN1KMT2AADORA3ADORA1DNPH1 | |
| SCHEMBL12376383 | 0.86 | ADORA3 (0.64) | MEN1KMT2AADORA3ADORA1DNPH1 | |
| SCHEMBL12360837 | 0.86 | ADORA3 (0.64) | MEN1KMT2AADORA3ADORA1DNPH1 | |
| SCHEMBL21999233 | 0.86 | ADORA3 (0.64) | MEN1KMT2AADORA3ADORA1DNPH1 | |
| SCHEMBL6223541 | 0.85 | ADORA3 (0.63) | MEN1KMT2AADORA3EHMT1ADORA1 | |
| SCHEMBL7902992 | 0.85 | ADORA1 (0.51) | MEN1KMT2AADORA3ADORA1DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-19 | — | — | US | disclosed |
| US-RE37077-E1 | Adenosine derivatives and pharmaceutical composition thereof | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADORA2A, PDE4A, PDE4D | MEN1 1161/4885KMT2A 485/4885ADORA3 27/4885 |
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADRB1, ADRB2, ADRA2B | MEN1 2943/4885KMT2A 2159/4885ADORA3 22/4885 |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | BCL6, BCL6B, BCL3 | MEN1 3082/4885KMT2A 1193/4885ADORA3 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.